> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# MoonLake Files FDA Approval Application For Skin Disease Drug Sonelokimab
- URL: https://www.bullished.co/moonlake-files-fda-approval-application-for-skin-disease-drug-sonelokimab-8dbe8fb7/
- Published: 2026-10-02T16:31:32.000Z
- Updated: 2026-10-06T08:45:38.000Z
- Description: The biologics license application covers moderate-to-severe hidradenitis suppurativa in adults and adolescents as young as 12.
- Author: Matteo Parrino
- Tags: SEC Filings, MLTX, Industry: Healthcare

MoonLake Immunotherapeutics [submitted a formal FDA approval application](https://www.sec.gov/Archives/edgar/data/0001821586/000121390026105240/ea0307097-8k%5Fmoonlake.htm?ref=bullished.co) for sonelokimab, its lead drug candidate, on Wednesday — putting the company on a regulatory clock that will determine whether the treatment for a painful chronic skin disease reaches the market. MLTX shares fell about 3% to $11.09 in Friday trading.

## What The 8-K Says

The company [filed a biologics license application](https://www.sec.gov/Archives/edgar/data/0001821586/000121390026105240/ea0307097-8k%5Fmoonlake.htm?ref=bullished.co) — the formal submission a company makes to the FDA requesting authorization to sell a biologic drug in the United States — seeking approval of sonelokimab for moderate-to-severe hidradenitis suppurativa in adults and pediatric patients 12 years of age and older.

Sonelokimab is what MoonLake describes as a tri-specific nanobody, a type of antibody fragment engineered to block multiple inflammatory targets at once. The application was signed by Chief Financial Officer Matthias Bodenstedt and filed with the SEC on Wednesday.

Hidradenitis suppurativa is a chronic inflammatory skin disease characterized by painful lesions and abscesses, typically in areas where skin rubs together. It has historically been difficult to treat.

## The Regulatory Clock

Two near-term milestones now govern the story. According to the 8-K filing, MoonLake expects the FDA to notify it whether the application has been accepted for review within about 60 days of submission. Acceptance is the threshold that starts a formal review clock.

Within about 74 days of submission, the company expects to receive the FDA's planned review timeline — the target decision date that investors will track as the clearest signal of when a potential approval could arrive.

Neither milestone is guaranteed. The 8-K's forward-looking statement section flags risks including the FDA declining to accept the submission, uncertainty around approval timing, and broader uncertainties tied to the company's limited operating history.

The first hard date to watch arrives roughly 60 days from Wednesday's submission, when the FDA is expected to tell MoonLake whether it will accept the application for a full review.

### Sources

- [8-K Filing — MoonLake Immunotherapeutics (MLTX)](https://www.sec.gov/Archives/edgar/data/0001821586/000121390026105240/ea0307097-8k%5Fmoonlake.htm?ref=bullished.co) — SEC EDGAR